Prostate-Specific Antigen–Based Screening for Prostate Cancer: A Systematic Evidence Review for the US Preventive Services Task Force: Evidence Synthesis No. 154. Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 17-05229-EF-1. 4. Fenton JJ, Weyrich MS, Durbin ...
An UpToDate review on "Screening for prostate cancer" (Hoffman, 2018) recommend prostate cancer screening beginning at age 40 to 45 years for men at high risk (e.g., black men, men with family history of prostate cancer, particularly in relatives younger than age 65, and men who are know...
The article offers information regarding prostate-specific antigen (PSA) tests employed for prostate cancer in the U.S. It says that U.S. Preventive Services Task Force (USPSTF) argues against PSA for 75 year olds and above because of insufficient data to assess the benefits and its harms. ...
Prostate Cancer Screening, Clinical Outcomes for Cancer Drugs Granted Accelerated Approval, Lupus Review, and more Editor’s Summary by Anne Rentoumis Cappola, MD, ScM, Associate Editor of JAMA, the Journal of the American Medical Association, for the May 7, 2024, issue....
The summary will be from the International Conference on Prostate Cancer Screening, Early Detection, and Control, convened in Atlanta, Ga, September 6 and 7 by the Centers for Disease Control and Prevention (CDC). The key questions before the 260 international and national experts gathered at th...
Age also affects prostate cancer survival rates. According to a CDC report, those under 50 and over 80 have the lowest relative survival rates. Because those under 50 aren't usually tested for prostate cancer, it may be less likely to be diagnosed in younger people until it reaches the late...
Despite the publication of thousands of articles on PSA and pros- tate cancer screening, the value of early intervention remains unclear.2,3 The PCA3 gene, formerly known as DD3, was first identified in 1999.2 PCA3 is a non–protein-coding messenger RNA (mRNA) that is highly overexpressed ...
Commentary Generalizability of Prostate-Specific Antigen (PSA) Screening Trials in a "Real World" Setting: A Nationwide Survey Analysis Deepansh Dalela, Akshay Sood, Jacob Keeley, Craig Rogers, Mani Menon, and Firas Abdollah COMMENTARY T he Prostate, Lung, Colorectal and Ovarian cancer (PLCO) ...
Overview of Prostate Cancer Screening Decision Models: A Contextual Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; April 2017. AHRQ publication 17-05229-EF-2. 6. US Preventive Services Task Force. US Preventive Services Task Force...
Prostate specific antigen screening has led to the early detection of prostate cancer. However, there has also been concern about the over diagnosis and overtreatment of patients with indolent cancers. We performed a population based analysis to evaluate the trade-off between excess treatment and prev...